NeoMatrix Awarded New Technology Agreement by Novation for HALO(R) Breast Pap Test
Published: Feb 02, 2010
IRVINE, Calif., Feb. 2 /PRNewswire/ -- NeoMatrix, Inc., developers of the innovative HALO(R) Breast Pap Test, has been awarded a new technology agreement by Novation, the supply contracting company of VHA Inc, University HealthSystem Consortium (UHC) and Provista. This agreement includes the HALO(R) Console, HALO(R) Cart, HALO(R) Patient Interface Cassette and HALO(R) Specimen Collection Cups.
"We are quite proud of being awarded this new technology agreement and look forward to a long-term, mutually beneficial partnership with Novation," said John Stroh, Chief Executive Officer and Director of NeoMatrix. "We consider this contract to be a sign of the dedication of NeoMatrix, Inc., to improving the breast health of women across the country."
HALO is designed as a complement to mammography and breast exams, the current standard screening for breast cancer. HALO is not a replacement for current routine screening with breast exams and mammograms. HALO is recommended annually for women over age 25. It is especially helpful for women who are too young for mammograms, or whose mammograms are less effective due to dense breast tissue that can obscure the detection of lesions.
Founded in 1998, Novation is the leading health care supply contracting company for more than 2,500 members of VHA Inc. and the University HealthSystem Consortium (UHC), two national health care alliances and nearly 14,000 members of Provista, LLC. Novation offers its customers contract development and management, supply chain data and measurement, and industry knowledge and advocacy. Based in Irving, Texas, Novation develops and manages competitive contracts with more than 500 suppliers. VHA, UHC and Provista members used Novation contracts to purchased nearly $35 billion in 2008. For more information on Novation, visit www.novationco.com.
CONTACT: Rebecca Farrell, +1-917-715-7840
Web site: http://www.neomatrix.com/